OBT

Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

Retrieved on: 
Thursday, March 7, 2024
OBT, Membrane, IO, Messenger, Therapeutic index, Spacecraft, Drug discovery, ADC, Conference, Proteomics, Chemistry, Toxicity, Partner, Patient, Protein, Science, Annual, Benchmarking, Tissue, Vaccine

“I am delighted to announce major technological advances with the launch of OBT’s OGAP-Verify target discovery platform.

Key Points: 
  • “I am delighted to announce major technological advances with the launch of OBT’s OGAP-Verify target discovery platform.
  • OGAP-verify is now more sensitive than IHC and allows for enhanced sensitivity with improved target selection, solving some of the challenges in antibody specificity,” said Christian Rohlff, CEO, Oxford BioTherapeutics.
  • “OBT is dedicated to discovering and validating the next generation of ADC targets for safe and effective medicines.
  • OBT is a Partner of the Annual World ADC Conference 2024 in London, UK.

Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

Retrieved on: 
Thursday, January 18, 2024
Hope, OBT, Neoplasm, Patient, Radiation therapy, MD, ADC, Neck, PD-1, Radiation, Head, NSCLC, ACC, Doctor of Philosophy, Antigen, Ovarian cancer, Lausanne University Hospital, Lung, CPI, CD205, Pharmaceutical industry

OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.

Key Points: 
  • OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.
  • The CD205 receptor is highly overexpressed in solid and liquid tumors with high unmet need, including gastric, lung and ovarian cancer.
  • We look forward to demonstrating the potential value of OBT076, with the hope to provide meaningful benefit for ACC patients.
  • Trial arms are investigating OBT076 both as a monotherapy and in combination with a CPI in these tumors.

CityLabs' Affiliated Company, CovenantLabs, 'Covenant Child' Global OBT begins

Retrieved on: 
Thursday, December 14, 2023
VIP, Human, Google Play, Motivation, OBT, CBT, Child, UTC, Immersion

SEOUL, KOREA, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Smart city integration platform company CityLabs' affiliated company, CovenantLabs, will end pre-orders for 'Covenant Child' on Wednesday, December 13 and start the global open beta test (OBT) on Thursday, December 14.

Key Points: 
  • SEOUL, KOREA, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Smart city integration platform company CityLabs' affiliated company, CovenantLabs, will end pre-orders for 'Covenant Child' on Wednesday, December 13 and start the global open beta test (OBT) on Thursday, December 14.
  • In this global open beta test (OBT) of 'Covenant Child' unlike CBT, some content has been improved and added, allowing for another exciting gameplay.
  • The improved and added content appeals to global users through various contents such as VIP system, hero promotion, hero Gacha system, and season pass.
  • Covenant Labs official said, "We ask for your participation in the global open beta test (OBT) starting at 6:00 (UTC) on Thursday, December 14.

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

Retrieved on: 
Wednesday, November 29, 2023
Partnership, Food, Drug discovery, Boehringer Ingelheim, FDA, Lung, Disease, Boehringer, News, Orphan drug, NEC, Carcinoma, OBT, SCLC, Patient, ADC, DLL3, Fast Track, Pharmaceutical industry

BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with LCNEC-Lung that is being developed by Boehringer Ingelheim.

Key Points: 
  • BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with LCNEC-Lung that is being developed by Boehringer Ingelheim.
  • The discovery of BI 764532 (OBT620) was enabled through a successful partnership initiated in 2013, leveraging OBT’s proprietary OGAP® drug discovery platform for identification of the DLL3 antigen and Boehringer Ingelheim’s longstanding expertise in oncology and development of biotherapeutics.
  • BI 764532 was also granted Orphan Drug designation by the FDA for the treatment of SCLC, and is currently being investigated in a Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ), in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory NEC.
  • Christian Rohlff, Chief Executive Officer of OBT, commented: “We are delighted about the clinical development to help address unmet needs for people living with small cell lung cancer and other neuroendocrine carcinomas.

Advito Partners with eco.mio to Bring GATE4 Emissions Methodology into Multiple Online Booking Tools

Retrieved on: 
Thursday, November 9, 2023
Air travel, Policy, Sustainability, Carbon, Organization, Atmosphere, OBT, Environment, Partnership, Travel, Culture, SAP Concur, Cryptocurrency, Transport

CHICAGO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Addressing the increasing need for accurate pre-trip emissions insights, Advito, a leading global travel consultancy, and eco.mio, an innovative leader in corporate travel sustainability solutions, have announced their partnership to integrate Advito's emissions data into eco.mio's gamification platform. Their aim is to highlight the most sustainable choices for business travelers in the air search of several online booking tools (OBTs). This partnership leverages eco.mio's robust integration capabilities and engaging gamification interface alongside Advito's ISO-certified GATE4 methodology, allowing travel managers to optimize air travel booking patterns in real-time and incentivize employees to opt for more sustainable travel choices.

Key Points: 
  • Their aim is to highlight the most sustainable choices for business travelers in the air search of several online booking tools (OBTs).
  • eco.mio seamlessly interfaces with established online booking tools like cytric, Egencia, and SAP Concur.
  • "We're excited to team up with eco.mio to revolutionize corporate travel sustainability and bring GATE4 directly into multiple OBTs," said Julien Etchanchu, Senior Director of Sustainability at Advito.
  • "By using the GATE4 emissions data, we are finally able to bring the most accurate calculation of business travel's climate impact into the booking process.

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers

Retrieved on: 
Tuesday, October 24, 2023
Patient, SCLC, US, Therapy, Antigen, US FDA, Neuroendocrine carcinoma of the cervix, Doctor of Philosophy, Carcinoma, OBT, NEC Laboratories America, ADC, Boehringer Ingelheim, Partnership, Cancer, Survival rate, Lymphocyte, DLL3, Vaccine, Pharmaceutical industry, Medicine

The Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ) is an open-label, multi-centre, dose-selection study evaluating two doses of BI 764532 in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory neuroendocrine carcinomas.

Key Points: 
  • The Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ) is an open-label, multi-centre, dose-selection study evaluating two doses of BI 764532 in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory neuroendocrine carcinomas.
  • Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics, said: “The start of this Phase 2 trial with BI 764532, the most advanced candidate with our partner Boehringer Ingelheim which was discovered using our proprietary OGAP® platform, is a major milestone for OBT.
  • Patients with neuroendocrine carcinomas, including small cell lung cancer, have a 5-year survival rate of approximately 13%.
  • BI 764532 was discovered using OBT’s proprietary OGAP® drug discovery platform and Boehringer Ingelheim’s longstanding expertise in oncology through a successful partnership initiated in 2013.

Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at The Oxford Science Park to Accelerate Development of its Immuno-Oncology and ADC-Based Cancer Therapies

Retrieved on: 
Wednesday, October 11, 2023
Doctor of Philosophy, Drug development, Erwin Schrödinger, University, Oxford Science Park, Growth, ADC, OBT, Research, Pharmaceutical industry

The new facilities comprise state-of-the-art office and custom laboratory spaces that will support and enhance OBT’s growing target discovery and drug development capabilities.

Key Points: 
  • The new facilities comprise state-of-the-art office and custom laboratory spaces that will support and enhance OBT’s growing target discovery and drug development capabilities.
  • OBT joins other innovative biotech companies and research institutes to make this transition, including the recently announced Oxford expansion of the Ellison Institute for Transformative Medicine.
  • OBT’s new headquarters will allow it to leverage the local network of high-quality talent, which benefits from its close proximity to the University of Oxford.
  • Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics, said: “We are excited to be moving to The Oxford Science Park, to work alongside many of the UK’s leading biotech companies.

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Boehringer, Glomus tumor, American Society of Clinical Oncology, OBT, Fast Track, SCLC, ASCO, U.S. FDA, Boehringer Ingelheim, DLL3, Patient, Antibody-drug conjugate, Annual general meeting, Drug discovery, Diagnosis, ADC, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Disease, Pharmaceutical industry

BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for treatment of patients with SCLC and other neuroendocrine tumors that is being developed by Boehringer Ingelheim.

Key Points: 
  • BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for treatment of patients with SCLC and other neuroendocrine tumors that is being developed by Boehringer Ingelheim.
  • Encouraging data were presented from the Phase I first-in-human dose-escalation trial at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
  • These Phase I data demonstrated a clinically acceptable safety profile and early efficacy in patients with DLL3-positive ES-SCLC and epNECs.
  • This is tremendously exciting for OBT, as it shows the real impact this partnership has for patients in need.

Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim’s Upcoming Transforming Science Day: Europe

Retrieved on: 
Tuesday, September 19, 2023
Science, Business development, Partnership, Boehringer, OBT, Francis Crick Institute, Boehringer Ingelheim, ADC, BST, Fine chemical

Oxford, UK, San Jose, Calif., 19th September 2023 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, announces that its Chief Executive Officer, Christian Rohlff, will participate in the panel discussion titled “It takes a village: A holistic approach to external innovation” at Boehringer Ingelheim’s upcoming Transforming Science Day: Europe.

Key Points: 
  • Oxford, UK, San Jose, Calif., 19th September 2023 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, announces that its Chief Executive Officer, Christian Rohlff, will participate in the panel discussion titled “It takes a village: A holistic approach to external innovation” at Boehringer Ingelheim’s upcoming Transforming Science Day: Europe.
  • The panel discussion will take place on 2 October 2023 at 13:15 British Summer Time (BST) in London.
  • Transforming Science Day is an event developed and funded by Boehringer Ingelheim.
  • The Transforming Science Day: Europe event will be hosted at The Francis Crick Institute, in London, and will also be streamed live on LinkedIn from 13:00 to 16:00 (BST).

Advito and Tripkicks Bring Point-of-Sale Carbon Emissions Measurement Capabilities to Hotel and Rail Travel

Retrieved on: 
Monday, August 14, 2023
Partnership, Travel, Senior, Atmosphere, Policy, OBT, Carbon, Sale, SAP Concur, Bloomberg, Air travel, Principal, Environment, Tourism, Online shopping

CHICAGO, Aug. 14, 2023 /PRNewswire-PRWeb/ -- In response to the continued demand for accurate pre-trip emissions data, leading global travel consultancy, Advito, and their partner, travel technology platform, Tripkicks, have expanded their ability to display GATE4 emissions figures in the SAP Concur online booking tool (OBT) to the hotel and rail search results pages. The solution leverages both Tripkicks' powerful integration capabilities and Advito's ISO-certified GATE4 methodology and complements the companies' existing capability to display these figures on the air search results page. The integration allows travel managers to optimize booking behavior in real-time while empowering employees to make more informed and sustainable choices.

Key Points: 
  • The integration allows travel managers to optimize booking behavior in real-time while empowering employees to make more informed and sustainable choices.
  • It is great to have two of our trusted partners develop a solution together that elevates our approach to sustainable travel."
  • Advito's hotel methodology accounts for crucial factors that affect emissions, like country-level electricity mix, market tier, amenities, occupancy rate, and energy usage.
  • "We are delighted to collaborate with Tripkicks in our shared commitment to transforming business travel and driving positive environmental change."